Subjective and objective evaluation of treatment with classic or atypical drugs in schizophrenia;Subiektywna i obiektywna ocena leczenia schizofrenii lekami klasycznymi i atypowymi

Psychiatria Polska

Volumn 35, Issue 1, 2001, Pages 5-19

  Jarema, M ^a   Murawiec, S ^a   Szafranski T ^a   Szaniawska, A ^a   Konieczynska Z ^a  

^a Instytut Psychiatrii i Neurologii III Klinika Psychiatryczna Warszawa   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; DRUG EFFECT; DRUG EFFICACY; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; PATIENT SATISFACTION; PIRENZEPINE; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0035055753     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Assessing depression in schizophrenia: The Calgary Depression Scale
2. Subjective response to neuroleptics in schizophrenia
3. Patients' subjective experiences on antipsychotic medications: Implications for outcome and quality of life
4. Brzemiȩ rodziny pacjentów ze schizofrenia̧ objȩtych różnymi formami opieki psychiatrycznej
5. Risperidone in the treatment of negative symptoms of schizophrenia: A meta-analysis
6. A self-rating scale for measuring neuroleptic side-effects. Validation in group of schizophrenic patients
7. Subjective utility ratings of neuroleptics in treating schizophrenia
8. Subjective response to antipsychotics in schizophrenic patients: Clinical implications and related factors
9. The St. Hans rating scale for extrapyramidal syndromes: Reliability and validity
10. Patient satisfaction and acceptability of long-term treatment with quetiapine
11. Subjective response to neuroleptics and outcome in schizophrenia: A re-examination comparing two measures
12. Badania kliniczne olanzapiny, przegla̧d piśmiennictwa
13. Farmakoterapia w nawrotach schizofrenii: Rola nowych atypowych neuroleptyków
14. First results of quality of life evaluation in treated schizophrenic patients
15. New atypical antipsychotic medications
16. An overview of patient satisfaction with psychiatric treatment
17. Risperidone and olanzapine: Optimal dosing for efficacy and tolerability in patients with schizophrenia
18. Positive and negative syndrome scale (PANSS) for schizophrenia
19. Badanie jakości życia zależnej od stanu zdrowia chorych leczonych z powodu schizofrenii w oddziale dziennym
20. Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics
21. The UKU side effect rating scale
22. Comparing response to "typical" and "atypical" antipsychotic drugs in schizophrenia: A multidimensional perspective
23. Subiektywne aspekty leczenia przeciwpsychotycznego w trakcie krótko- i dlugoterminowej farmakoterapii schizofrenii
24. A self-rating to measure subjective effects of neuroleptic drugs, relationship to objective psychopathology, quality of life, compliance and other clinical variables
25. Subjective experiences of schizophrenic patients treated with antipsychotic medication
26. Patients assessment of treatment predicting outcome
27. Znaczenie kliniczne skal samooceny u chorych na schizofreniȩ
28. Dysphoric response of neuroleptic treatment in schizophrenia: Its relationship to autonomic arousal and prognosis
29. Porównanie olanzapiny i haloperidolu w leczeniu schizofrenii, psychozy schizoafektywnej i zaburzeń schizofrenopodobnych. Wyniki miȩdzynarodowego badania klinicznego
30. Subjective response as a predictor of outcome in pharmacotherapy
31. Subjective response to antipsychotic drugs
32. Treatment of refractory rapid cycling bipolar disorder with risperidone
33. Patient attitudes toward mental hospitalization: W review of quantitative research
34. Clinical predictors of acute response with olanzapine in psychotic mood disorders